1Tenney DJ,Levine SM,Rose RE,et al.Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine[].Antimicrobial Agents and Chemotherapy.2004 被引量：1
2Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Long-termtherapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B[].The New England Journal of Medicine.2005 被引量：1
3Dienstag JL,Goldin RD,Heathcote EJ,et al.Histological outcome during long-termlamivudine therapy[].Gastroenterology.2003 被引量：1
4Lok AS,Lai CL,Leung N,et al.Long-termsafety of lamivudinetreatment in patients with chronic hepatitis B[].Gastroenterology.2003 被引量：1
5Lok AS,Lai CL,Leung N,et al.Long-termsafety of lamivudinetreatment in patients with chronic hepatitis B[].Gastroenterology.2003 被引量：1
6Chang TT,Lai CL,Chien RN,et al.Four years of lamivudinetreatmentin Chinese patients with chronic hepatitis B[].Journal of Gastroenterology.2004 被引量：1
7Liaw YF,Chien RN,Yeh CT,Tsai SL,Chu CM.Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy[].Hepatology.1999 被引量：1
8Qi X,Zhu Y,Curtis M,et al.Invitro cross-resistance analysis of the HBV polymerase mutation A181V.Program and abstracts of the40th Annual Meeting of the European Association for the Study of the Liver;April13-17,2005;Paris,France[].Abstract. 被引量：1
9Schildgen O,Sirma H,Funk A,et al.Variant of hepatitis Bvirus with pri-mary resistance to adefovir[].The New England Journal of Medicine.2006 被引量：1
10LimSG,Hadziyannis S,Tassopoulos Net al.Clinical profile of HBeAg-chronic hepatitis B patients with adefovir dipivoxil resistance mutations.Programand abstracts of the40th Annual Meeting of the European Associa-tionforthe Study of the Liver;April13-17,2005;Paris,France[].Abstract. 被引量：1
5Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
